Orion Oyj B Asset Resilience Ratio
Orion Oyj B asset resilience ratio. Orion Oyj B (ORNBV) has an Asset Resilience Ratio of 11.16% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Orion Oyj B (ORNBV) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Orion Oyj B (2000–2022)
Asset resilience ratio of Orion Oyj B from 2000 to 2022. This chart shows how Orion Oyj B's Asset Resilience Ratio has changed over time. Read Orion Oyj B (ORNBV) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Orion Oyj B's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Orion Oyj B assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €183.60 Million | 11.16% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €183.60 Million | 11.16% |
Asset Resilience Insights
- Moderate Liquidity: Orion Oyj B has 11.16% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Orion Oyj B Industry Peers by Asset Resilience Ratio
Compare Orion Oyj B's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.33% |
|
Novartis AG
MX:NVSN |
Drug Manufacturers - General | 0.08% |
|
Biogen Inc
NASDAQ:BIIB |
Drug Manufacturers - General | 0.00% |
|
Organon & Co
NYSE:OGN |
Drug Manufacturers - General | 4.46% |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019 |
Drug Manufacturers - General | 0.53% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
Orion Oyj B Asset Resilience Ratio by Year (2000–2022)
Orion Oyj B asset resilience ratio by year from 2000 to 2022. The table below shows the annual Asset Resilience Ratio data for Orion Oyj B.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.07% | €-1.00 Million ≈ $-1.17 Million |
€1.50 Billion ≈ $1.76 Billion |
+1.32pp |
| 2021-12-31 | -1.38% | €-15.40 Million ≈ $-18.00 Million |
€1.11 Billion ≈ $1.30 Billion |
-1.34pp |
| 2020-12-31 | -0.04% | €-500.00K ≈ $-584.55K |
€1.12 Billion ≈ $1.30 Billion |
-3.52pp |
| 2019-12-31 | 3.48% | €36.00 Million ≈ $42.09 Million |
€1.04 Billion ≈ $1.21 Billion |
-0.80pp |
| 2018-12-31 | 4.27% | €49.00 Million ≈ $57.29 Million |
€1.15 Billion ≈ $1.34 Billion |
+9.66pp |
| 2017-12-31 | -5.39% | €-56.90 Million ≈ $-66.52 Million |
€1.06 Billion ≈ $1.23 Billion |
-8.31pp |
| 2016-12-31 | 2.92% | €31.00 Million ≈ $36.24 Million |
€1.06 Billion ≈ $1.24 Billion |
+5.64pp |
| 2015-12-31 | -2.72% | €-28.50 Million ≈ $-33.32 Million |
€1.05 Billion ≈ $1.22 Billion |
-10.01pp |
| 2014-12-31 | 7.29% | €73.00 Million ≈ $85.34 Million |
€1.00 Billion ≈ $1.17 Billion |
+10.13pp |
| 2013-12-31 | -2.84% | €-27.80 Million ≈ $-32.50 Million |
€979.00 Million ≈ $1.14 Billion |
+2.19pp |
| 2011-12-31 | -5.03% | €-39.20 Million ≈ $-45.83 Million |
€779.10 Million ≈ $910.85 Million |
-15.45pp |
| 2010-12-31 | 10.42% | €77.70 Million ≈ $90.84 Million |
€745.80 Million ≈ $871.92 Million |
-5.74pp |
| 2006-12-31 | 16.15% | €95.00 Million ≈ $111.06 Million |
€588.10 Million ≈ $687.55 Million |
+9.01pp |
| 2004-12-31 | 7.14% | €81.10 Million ≈ $94.81 Million |
€1.14 Billion ≈ $1.33 Billion |
-2.05pp |
| 2003-12-31 | 9.20% | €112.80 Million ≈ $131.88 Million |
€1.23 Billion ≈ $1.43 Billion |
-1.59pp |
| 2002-12-31 | 10.79% | €152.10 Million ≈ $177.82 Million |
€1.41 Billion ≈ $1.65 Billion |
-9.19pp |
| 2001-12-31 | 19.98% | €189.50 Million ≈ $221.55 Million |
€948.50 Million ≈ $1.11 Billion |
-2.31pp |
| 2000-12-31 | 22.29% | €203.90 Million ≈ $238.38 Million |
€914.60 Million ≈ $1.07 Billion |
-- |
About Orion Oyj B
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides pharmaceutical products, which includes Nubeqa for the treatment of prostate cancer; Entacapone, Stalevo, Comtess, and Comtan to treat Parkinson's disease; Burana for inflam… Read more